Linh has extensive experience in securities litigation, complex civil litigation and class action defense. She has represented clients in various industries – such as biotechnology, pharmaceutical and cannabis companies – in a range of civil litigation matters, including actions asserting violations of federal and/or state securities laws, breach of fiduciary duty, derivative suits, breach of contract, and unfair competition. In the technology space, she has litigated high-profile matters for clients in cutting-edge cases, including actions involving Section 230 of the Communications Decency Act (CDA).

Download full bio 


  • Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion 


  • University of California at Davis King Hall School of Law
    JD, 2015

  • Brown University
    BA, International Relations

Admissions & Credentials